DSS, Inc. Reports Strong Q1 2025 Financial Performance, Setting the Stage for Strategic Growth

Rhea-AI Summary

DSS reported strong Q1 2025 financial results, demonstrating significant progress in its financial repositioning strategy. The company achieved 28% year-over-year revenue growth, driven by a 30% increase in printed product sales and an impressive 78.5% growth in rental income from $400,000 to $714,000. Key financial highlights include the successful sale of its Plano, TX facility for $9.5 million, debt reduction of over $8 million, and a $1.5 million equity capital raise through Impact BioMedical. Operating cash flow improved, with net cash used in operations decreasing from $2.15 million in Q1 2024 to $1.64 million in Q1 2025.

Positive

• 28% year-over-year revenue growth with 30% increase in printed product sales
• 78.5% growth in rental income from real estate segment ($400,000 to $714,000)
• Successfully sold Plano facility for $9.5 million
• Reduced total debt by over $8 million
• Raised $1.5 million in new equity capital through Impact BioMedical
• Improved operating cash flow with reduced cash burn ($2.15M to $1.64M)

Negative

• Still operating at a cash loss with $1.64 million used in operations

NEW YORK, May 22, 2025 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS), a multinational company operating across diverse industries including packaging, real estate, and biomedical innovation, today announced financial results for the first quarter of 2025, highlighting meaningful progress in its financial repositioning and a strong foundation for corporate execution in the coming quarters.

In a quarter focused on streamlining operations and financial discipline, DSS delivered significant improvements in key financial metrics:

• 28% Year-Over-Year Revenue Growth: Total revenues rose sharply, fueled by a 30% increase in printed product sales and a nearly doubling of rental income from the company’s real estate segment, which grew from $400,000 to $714,000.

• Strategic Asset Monetization: The Company completed the sale of its Plano, TX facility, for $9.5 million, contributing to $12.88 million in cash from investing activities during the quarter.

• Debt Reduction and Capital Discipline: DSS used proceeds from asset sales and investments to pay down over $8 million in total debt, reflecting a clear commitment to balance sheet optimization.

• Strengthening Shareholder Equity: Through its partner company Impact BioMedical, DSS raised $1.5 million in new equity capital during Q1.

• Improved Operating Cash Flow: Net cash used in operations improved from $2.15 million in Q1 2024 to $1.64 million in Q1 2025, underscoring early operational efficiencies.
  

“These results show clear, measurable progress in the financial realignment strategy we launched earlier this year,” said Jason Grady, CEO of DSS, Inc. “In my January letter to shareholders, I outlined the urgent need to cut inefficiencies, strengthen our balance sheet, and lay the groundwork for sustained growth. This quarter proves that work is paying off. As we continue to streamline operations, we’re now turning our attention toward execution in our core verticals and identifying smart, accretive opportunities that will drive long-term value. The foundation is in place and now we’re building on it.”

The Company plans to continue to showcase measurable results from initiatives in development, operations, and M&A activity as the year progresses. With a renewed focus on high-potential business units and capital allocation, DSS is positioning itself for a dynamic second half of 2025 and beyond.

To read the 2025 CEO shareholder letter, visit: investors.dssworld.com

Forward-looking Statements:

The foregoing material may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation statements regarding the Company’s product development and business prospects, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of risks and uncertainties that could significantly affect current plans. Should one or more of these risks or uncertainties materialize, or the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee future results, performance, or achievements. Except as required by applicable law, including the security laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to actual results.

About DSS, Inc.:

DSS, Inc. (NYSE American: DSS) is a multinational company operating businesses across multiple high-growth sectors. DSS focuses on creating, acquiring, and investing in innovative companies that drive sustainable value for its shareholders.

For investor and media inquiries or additional information, please contact:

DSS, Inc. Investor Relations
Email: IR@dssworld.com
Phone: +1 (585) 565-2422

FAQ

What was DSS's revenue growth in Q1 2025?

DSS reported a 28% year-over-year revenue growth in Q1 2025, driven by a 30% increase in printed product sales and nearly doubling of rental income.

How much debt did DSS pay down in Q1 2025?

DSS paid down over $8 million in total debt during Q1 2025 using proceeds from asset sales and investments.

How much did DSS sell its Plano, TX facility for?

DSS sold its Plano, TX facility for $9.5 million, contributing to $12.88 million in cash from investing activities during Q1 2025.

What was DSS's operating cash flow improvement in Q1 2025?

DSS improved its net cash used in operations from $2.15 million in Q1 2024 to $1.64 million in Q1 2025.

How much equity capital did DSS raise through Impact BioMedical in Q1 2025?

DSS raised $1.5 million in new equity capital through its partner company Impact BioMedical during Q1 2025.